IVA Articles, Inventiva S.A.

Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceu...

Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmace...

Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022  Cash and cash equivalents at €26.9 millio...

Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company f...

LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with emp...

Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmace...

Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central I...

Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quart...

On Friday, in its fourth-quarter 2023 earnings release, Inventiva SA (NASDAQ:IVA) said it has voluntarily paused screening and randomizat...

Shares of The Trade Desk, Inc. (NASDAQ: TTD) shares rose sharply in today’s pre-market trading after the company reported mixed fourth-quart...